CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CNBX Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CNBX Pharmaceuticals Inc
#3 Bethesda Metro Center, Suite 700
Phone: (877) 424-2429p:877 424-2429 BETHESDA, MD  20814  United States Ticker: CNBXCNBX
Business Summary
CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
5/31/20248/31/2023YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board GabrielYariv 45 9/5/2021 10/2/2019
Chief Executive Officer, Director EyalBarad 57 1/29/2018 11/13/2017
Chief Financial Officer UriBen-Or 53 11/5/2016 11/5/2016
Chief Technology Officer SanjaGoldberg 46 7/24/2022 7/24/2022

Business Names
Business Name
8C8
CNBX
CNBXD
4 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 8/31/2023)
Outstanding Shares: 31,111,352 (As of 7/14/2024)
Shareholders: 57
Stock Exchange: OTC
Federal Tax Id: 203373669


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024